Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hirata, M.
Right arrow Articles by Fukagawa, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hirata, M.
Right arrow Articles by Fukagawa, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 37-40
© 2002 European Renal Association-European Dialysis and Transplant Association


A comparison between daily and thrice-weekly i.v. administration of 1,25-dihydroxy-22-oxavitamin D3 regarding suppression of parathyroid hormone secretion and calcaemic action in uraemic rats

Michinori Hirata1,, Koichi Endo1, Hiroyuki Ohkawa1, Kenji Kumaki1, Noboru Kubodera1, Eduardo Slatopolsky2, Kiyoshi Kurokawa3 and Masafumi Fukagawa4

1 Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd, Gotemba, Shizuoka, Japan, 2 Department of Internal Medicine, Renal Division, Washington University School of Medicine, St Louis, Missouri, USA, 3 Tokai University School of Medicine, Isehara, Japan and 4 Division of Nephrology and Dialysis Center, Kobe University School of Medicine, Kobe, Japan

Abstract

Background. 1,25-Dihydroxy-22-oxavitamin D3 (22-oxacalcitriol, OCT) is an analogue of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3, calcitriol) with less calcaemic activity, thus more suitable than 1,25(OH)2D3 for the control of parathyroid hormone (PTH) secretion in chronic dialysis patients. As the low-calcaemic action of OCT has been mainly attributed to its short half-life in the blood stream, the number of doses per week is the key factor to effective OCT therapy toward suppression of PTH secretion and hypercalcaemia. Thus, we investigated a comparison between daily and thrice-weekly i.v. administration of OCT regarding suppression of PTH secretion and calcaemic action in 5/6 nephrectomized rats as a model for chronic renal failure.

Methods. Model rats of chronic renal failure were made by 5/6 nephrectomy. At 3 months after surgery, they were administered either vehicle or OCT intravenously, daily (0.125 or 0.625 µg/kg) or thrice-weekly (0.6 or 3.0 µg/kg) for 2 weeks.

Results. The data show that 0.625 µg/kg/day (=4.375 µg/kg/week) suppresses PTH secretion with significant increase in calcium levels at 24 h after the final administration, on the other hand, 3.0 µg/kg/ thrice-weekly (=9.0 µg/kg/week) suppresses PTH secretion, although moderate compared with 0.625 µg/kg/day, with a slight (not significant) increase in calcium.

Conclusions. The current clinical mode of OCT therapy, i.v. thrice-weekly administration, is a practically recommendable protocol.

Keywords: calcaemic action; OCT; parathyroid hormone; secondary hyperparathyroidism; uraemia; vitamin D analogue

Notes

Correspondence and offprint requests to: Michinori Hirata, PhD, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd, 1-135 Gotemba, Shizuoka 412-8513, Japan. Email: hiratamcn{at}chugai\|[hyphen]\|pharm.co.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.